" class="no-js "lang="en-US"> Almirall - Medtech Alert
Friday, August 01, 2025
Almirall | Pharmtech Focus

Almirall

About Almirall

Almirall

Almirall is a global biopharmaceutical company focused on skin health. Founded in 1943 and with headquarters in Barcelona (Spain), our Noble Purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. Through pharmaceutical innovation, investment in R&D and strong commitment to global healthcare partnerships, we develop and commercialize solutions with specific focus on dermatological diseases such as psoriasis, actinic keratosis, atopic dermatitis or acne. We care and listen to our patients’ needs. We find solutions for them. We aim to empower them. Almirall has 2 R&D centers, 2 chemical plants and 2 pharmaceutical plants. Our close to 1,800 employees make it possible for our treatments to be available in over 70 countries across 5 continents, through our 13 global affiliates and via a strategic partnership network. Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and joined the IBEX 35 Index in 2020.

Related Story

Almirall Appoints Mercedes Diz as VP, Corporate Strategy

December 14 2022

Almirall, a global biopharmaceutical company focused on skin health, today announced that Mercedes Diz will […]

Almirall Joins FACILITATE, a Patient-driven Innovative Medicines Initiative (IMI) Project

November 28 2022

Almirall (ALM), a global biopharmaceutical company focused on skin health, has today announced that it […]

Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

April 12 2022

At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined […]